28 July 2023
28 July 2023
The company has raised a total exceeding $430m in the Series C round, as it prepares to move its gene therapies into the clinic.
The approval is based on data from the multicentre, open-label, Phase III TROPiCS-02 study.
The models within InSilicoNEURO will be leveraged to evaluate the potential of Axoltis' drug candidate on virtual patients.
Axolotl shareholders will receive an initial equity value of $65m and up to $75m in potential milestone equity payments.
Organ-on-chip? How about a human-on-chip – the device that DLOC and new partners 42 Technology aim to bring to market.
Potential causes of endometriosis include genetics and malfunctions of the immune system.
Nine of the top 20 companies demonstrated a positive compound annual growth rate exceeding 10% between 2018 and 2022.
The company attributed the decline in sales in Q2 2023 to reduced sales of Revlimid.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
